Featured Research

from universities, journals, and other organizations

"Translocation" Surgery Yields Unprecedented Results; Offers Hope For Patients With Early-Stage Macular Degeneration

Date:
December 13, 2000
Source:
Johns Hopkins Medical Institutions
Summary:
An operation developed at Johns Hopkins to halt blinding retinal damage from age-related macular degeneration (AMD) improved vision in nearly half of the first 100 patients treated, according to a recent report in the American Journal of Ophthalmology. The operation, macular translocation, moves the central, most light-sensitive part of the retina away from an overgrowth of abnormal blood vessels that bleed and damage retinal tissue.

An operation developed at Johns Hopkins to halt blinding retinal damage from age-related macular degeneration (AMD) improved vision in nearly half of the first 100 patients treated, according to a recent report in the American Journal of Ophthalmology.

Related Articles


"Six months after surgery, 48 percent of our patients could read an additional two lines on a standard eye chart or had vision of 20/100 or better -- enough to legally drive in the state of Maryland -- and 16 percent could read an additional six lines on the eye chart," says Eugene de Juan, M.D., professor of ophthalmology at Hopkins' Wilmer Eye Institute. "No other treatment for AMD comes even close to that. These are the best results ever recorded."

The operation, macular translocation, moves the central, most light-sensitive part of the retina away from an overgrowth of abnormal blood vessels that bleed and damage retinal tissue. The procedure is useful only for people newly diagnosed with this so-called wet form of AMD. AMD is the major cause of blindness in people age 55 and older.

In the surgery, de Juan pinches the sclera, the white, outer skin of the eyeball, as if it were a hollow rubber ball, then puts sutures into the side wall of the eye to keep it pinched, shortening its length. This buckles the retina, which lines the inner wall of the eyeball. De Juan next injects a salty solution into the eye under the retina, causing the retina to "blister" enough to be moved slightly without detaching it. The average distance the retina must be moved is only about 0.3 to 0.4 millimeters -- about .01 inches.

The report, published in the October issue of the journal, chronicles results of the procedure in 102 eyes in the first 101 consecutive patients. Patients ranged in age from 41 to 89; 60 percent were male. Within three months following surgery, 37 percent of the patients gained two or more lines of vision on a standard eye chart compared to measurements taken before surgery. Within six months following surgery, 48 percent of patients experienced similar vision improvement, and 10 percent had vision better than 20/40.

Patients with worse preoperative vision or who developed complications, most commonly retinal detachment, did not improve.

Other treatments for AMD include laser photocoagulation and photodynamic therapy (PDT). In the first, a laser beam is used to destroy abnormal blood vessels, but few patients maintain enough central vision to permit reading or driving, and the laser could harm surrounding tissue.

Photodynamic therapy combines the use of a light-sensitive medication and a laser light beamed into the eye. The laser is too weak by itself to have any effect on the retina, but it activates the drug, which produces a toxic, reactive form of oxygen that can damage the diseased tissue and blood vessels while leaving healthy cells alone. PDT can't restore vision, but it can halt the progression of the disease. De Juan says the fix is temporary, and some patients who receive PDT need surgery later.

De Juan stresses the importance of early management of AMD: "Macular translocation is effective only for people just diagnosed. Once they've had the disease for a few months, it may be too late." To date, he has performed close to 400 of the operations.

The study's other authors were Dante J. Pieramici, M.D.; G.Y. Fujii; S.M. Reynolds; M. Melia; Mark S. Humayun, M.D., Ph.D.; Andrew P. Schachat, M.D.; and Craig D. Hartranft, M.D.

Related Web sites: Wilmer Eye Institute at Johns Hopkins http://www.wilmer.jhu.edu


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. ""Translocation" Surgery Yields Unprecedented Results; Offers Hope For Patients With Early-Stage Macular Degeneration." ScienceDaily. ScienceDaily, 13 December 2000. <www.sciencedaily.com/releases/2000/12/001208074447.htm>.
Johns Hopkins Medical Institutions. (2000, December 13). "Translocation" Surgery Yields Unprecedented Results; Offers Hope For Patients With Early-Stage Macular Degeneration. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2000/12/001208074447.htm
Johns Hopkins Medical Institutions. ""Translocation" Surgery Yields Unprecedented Results; Offers Hope For Patients With Early-Stage Macular Degeneration." ScienceDaily. www.sciencedaily.com/releases/2000/12/001208074447.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins